Scholars Central

Conference abstractPublished 18 Nov 2025

Inflammatory bowel disease

Authors: Calvin Moses Kalukursa

HelpAge India

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Inflammatory Bowel Disease (IBD), comprising Crohn’s disease and ulcerative colitis, represents a chronic, relapsing remitting inflammatory disorder of the gastrointestinal tract with significant global health impact. Its incidence has increased markedly over the past decades, particularly in developing regions undergoing rapid urbanization. While the exact etiology of IBD remains multifactorial, current evidence indicates a complex interplay among genetic susceptibility, environmental triggers, gut microbiota dysbiosis, and dysregulated mucosal immune responses. These interactions lead to chronic intestinal inflammation, epithelial barrier dysfunction, and progressive tissue damage. Clinically, IBD manifests with abdominal pain, diarrhoea, rectal bleeding, weight loss, extraintestinal complications, and impaired quality of life. Diagnosis relies on a combination of endoscopic evaluation, histopathology, biomarkers, and advanced imaging. Despite substantial advancements, early detection remains challenging due to overlapping symptoms with infectious and functional bowel disorders. Therapeutic strategies for IBD have expanded significantly, moving beyond traditional corticosteroids and immunomodulators. Biologic agents targeting TNF-α, IL-12/23 pathways, integrins, and JAK inhibitors have transformed disease management, providing improved remission rates and mucosal healing. Recent research highlights the importance of personalized medicine through biomarker-guided therapy, microbiome modulation, nutritional interventions, and emerging cell-based treatments, including mesenchymal stem cell therapy. Additionally, non-invasive monitoring using faecal calprotectin and novel imaging biomarkers is improving long-term disease assessment and relapse prediction. Despite these advances, unmet needs remain in understanding disease heterogeneity, preventing complications, and improving patient-centric outcomes. Future directions focus on precision therapeutics, early intervention strategies, and integrative approaches combining pharmacological, dietary, and lifestyle management to optimize long-term remission.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in Journal of Hepatology and Gastrointestinal disorders.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Hepatology and Gastrointestinal disorders
  • SubjectGastroenterology & Hepatology
  • BylineArticles whose byline prints “Calvin Moses Kalukursa”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels